Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 2/20 | 0.43 |
| ▸ | CTSA | P10619 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7045677 | 0.83 | HDAC1 (0.46) | P2RX7L3MBTL1KMT2AKDM4EALDH1A1 | |
| SCHEMBL30695551 | 0.83 | PLK1 (0.46) | P2RX7GAAL3MBTL1KMT2AKDM4E | |
| SCHEMBL8568914 | 0.83 | PLK1 (0.46) | P2RX7GAAL3MBTL1KMT2AKDM4E | |
| SCHEMBL162188 | 0.82 | L3MBTL1 (0.50) | P2RX7L3MBTL1KMT2AKDM4ENOS3 | |
| SCHEMBL13310736 | 0.82 | PARP1 (0.48) | P2RX7L3MBTL1KMT2AKDM4EKIT | |
| SCHEMBL10517292 | 0.81 | GRM5 (0.45) | P2RX7L3MBTL1KMT2AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL28847816 | 0.81 | L3MBTL1 (0.49) | P2RX7L3MBTL1KMT2AKDM4ENOS3 | |
| Hydrochloric Acid SCHEMBL6385939 | 0.81 | L3MBTL1 (0.49) | P2RX7L3MBTL1KMT2AKDM4ENOS3 | |
| Hydrochloric Acid SCHEMBL10707149 | 0.80 | CHEK1 (0.47) | P2RX7KMT2AKDM4EFDPSCTSA | |
| SCHEMBL24571662 | 0.80 | CTSA (0.49) | L3MBTL1KMT2AKDM4EKITFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3388428-B1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-10821104-B2 | Five-membered heterocyclic amides WNT pathway inhibitor | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-03 | — | — | US | disclosed |
| EP-3630752-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018222795-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-06 | — | — | WO | disclosed |
| US-9868721-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2018-01-16 | — | — | US | disclosed |
| WO-2017097216-A9 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | 杭州雷索药业有限公司 | 2017-11-23 | — | — | WO | disclosed |
| WO-2017097216-A1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | 杭州雷索药业有限公司 | 2017-06-15 | — | — | WO | disclosed |
| US-9656998-B2 | Intermediates for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170042897-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-6528093-B1 | Dissolving leuprorelin in an orgaic solvent of hydrocarbon halides, alkyl ethers or esters and aromatic hydrocarbons along with glycolic acid-lactic acid copolymer; adding a water mixture and desolventizing to form microcapsules | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-03-04 | — | — | US | disclosed |
| US-20030039698-A1 | SUSTAINED-RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2003-02-27 | — | — | US | disclosed |
| US-20020173467-A1 | Sustained-release preparation | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2002-11-21 | — | — | US | disclosed |
| US-20020147150-A1 | Sustained-release preparation | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2002-10-10 | — | — | US | disclosed |
| EP-0601799-B1 | Sustained-release preparation | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-08-08 | — | — | EP | disclosed |
| EP-1088555-A1 | Sustained-release preparation | Takeda Chemical Industries, Ltd. (JP) | 2001-04-04 | — | — | EP | disclosed |
| US-5972891-A | A MIXTURE COMPRISING AN ACTIVE NONAPEPTIDE OR DECAPEPTIDE AND A BIODEGRADABLE POLYMER HAVING A TERMINAL CARBOXYL GROUP, SHOWING CONSTANT RELEASE OF THE PEPTIDE OVER A LONG TIME | TAKEDA CHEMICAL INDUSTRIES, LTD. (FR) | 1999-10-26 | — | — | US | disclosed |
| US-5668111-A | POLYPEPTIDE HORMONE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-16 | — | — | US | disclosed |
| US-5480868-A | Sustained-release preparation | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-02 | — | — | US | disclosed |
| EP-0601799-A1 | Sustained-release preparation | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030039698-A1 | SUSTAINED-RELEASE PREPARATION | ARGLU1, NGLY1, NPR1 | P2RX7 1906/4885GAA 235/4885L3MBTL1 2820/4885 |
| US-10821104-B2 | Five-membered heterocyclic amides WNT pathway inhibitor | WNT1, WNT3, WNT3A | P2RX7 3229/4885GAA 2510/4885L3MBTL1 2528/4885 |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | P2RX7 112/4885GAA 3932/4885L3MBTL1 4796/4885 |
| US-20020173467-A1 | Sustained-release preparation | ARGLU1, NGLY1, NPR1 | P2RX7 1906/4885GAA 235/4885L3MBTL1 2820/4885 |
| US-20020147150-A1 | Sustained-release preparation | ARGLU1, NGLY1, NPR1 | P2RX7 1906/4885GAA 235/4885L3MBTL1 2820/4885 |
| US-20170042897-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | P2RX7 112/4885GAA 3932/4885L3MBTL1 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.